hapabapa/iStock Editorial via Getty Images
Novo Nordisk (NVO) has initiated a new Phase 3 trial for its next-gen weight loss therapy CagriSema after the Danish drugmaker’s REDEFINE 1 Phase 3 trial for the treatment disappointed Wall Street late last year.
Shares of the Wegovy maker
